Patent US4778787A successfully refreshed from Google Patents.
US4778787A
Expired / Lapsed
US
⏱️ 0.0 years remaining
Method for treatment of angina and myocardial infarctions with omental lipids
Assignee: ANGIO-MEDICAL CORP A CORP OF
•
Filing: 1985-12-20
•
Granted: 1988-10-18
•
Expires: 2005-12-20
Abstract
Abstract Angiogenesis healing factors residing in omentum-derived lipid fractions with or without gangliosides or their synthetic equivalents can be used to treat myocardial ischemic conditions including but not limited to myocardial infarction, angina, as well as in heart transplant, vascular grafts, and re-opened vessels leading to improved vascularization, perfusion, collagenization and organization of said lesions; the involved and adjacent tissues.
Inventors
- 👤 Nicholas Catsimpoolas
- 👤 Haralambos Gavras
- 👤 Christian C. Haudenschild
- 👤 Michael I. Klibaner
Bibliographic Details
Application Number
—
Jurisdiction
US
Data Source
google_patents
Last Synchronized
2026-10-23 18:09
CPC Classifications
A; A61; A61K; A61K38/00; A61K35/00; A61K35/12; A61K35/37; A61K31/00
Claims Analysis
Total Claims: 33
Claim 1
Independent Claim
50 words
Composition for the treatment of angina, a myocardial ischemic lesion, or a myocardial infarct in a human having angina, a myocardial infarct or a myocardial ischemic lesion consisting essentially of a pharmacologically active mixture of lipid and ganglioside derived from the omentum by extraction with at least one organic solvent.
Claim 2
Dependent Claim
50 words
Composition for the treatment of angina, a myocardial ischemic lesion, or a myocardial infarct in a human having angina, a myocardial infarct or a myocardial ischemic lesion consisting essentially of a pharmacologically active mixture of lipid and ganglioside derived from the omentum by extraction with at least one organic solvent.
Claim 3
Dependent Claim
37 words
Composition for the treatment of angina, a myocardial ischemic lesion, or a myocardial infarct in a human having angina, a myocardial infarct or a myocardial ischemic lesion wherein the composition consists essentially of pharmacologically active lipid material.
Claim 4
Dependent Claim
37 words
Composition for the treatment of angina, a myocardial ischemic lesion, or a myocardial infarct in a human having angina, a myocardial infarct or a myocardial ischemic lesion wherein the composition consists essentially of pharmacologically active lipid material.
Claim 5
Dependent Claim
37 words
Composition for the treatment of angina, a myocardial ischemic lesion, or a myocardial infarct in a human having angina, a myocardial infarct or a myocardial ischemic lesion wherein the composition consists essentially of pharmacologically active ganglioside material.
Claim 6
Dependent Claim
37 words
Composition for the treatment of angina, a myocardial ischemic lesion, or a myocardial infarct in a human having angina, a myocardial infarct or a myocardial ischemic lesion wherein the composition consists essentially of pharmacologically active ganglioside material.
Claim 7
Dependent Claim
18 words
Composition of claim 1 wherein the omentum lipid mixture is a physiologically active chloroform methanol extract of omentum.
Claim 8
Dependent Claim
14 words
Composition of claim 1 wherein the omentum mixture is a physiologically active hexane-ethanol extract.
Claim 9
Dependent Claim
17 words
Composition of claim 5 wherein the hexane-ethanol extract is derived from further extraction of the chloroform-methanol extract.
Claim 10
Dependent Claim
16 words
Composition of claim 1 wherein the composition is a physiologically active supercritical gas extract of omentum.
Claim 11
Dependent Claim
36 words
Composition of claim 1, 2 or 3, wherein the essentially ganglioside, lipid or ganglioside-lipid-omental material leads to improved vascularization and collateralization in angina, a myocardial ischemic lesion or a myocardial infarction and tissue bordering the infarction.
Claim 12
Dependent Claim
40 words
Composition of claim 1, 2 or 3, wherein the essentially ganglioside, lipid or ganglioside-lipid-omental material leads to improved vascularization and collateralization allowing improved myocardial perfusion in angina, a myocardial ischemic lesion, or a myocardial infarction and tissue bordering the infarction.
Claim 13
Dependent Claim
35 words
Composition of claims 1, 2 or 3, wherein the essentially ganglioside, lipid or ganglioside-lipid-omental material leads to improvement of myocardial perfusion in angina, a myocardial ischemic lesion, a myocardial infarction or tissue bordering the infarction.
Claim 14
Dependent Claim
33 words
Composition of claim 1, 2 or 3, wherein the essentially ganglioside, lipid or ganglioside-lipid-omental material leads to increased or accelerated organization and collagenization in angina, a myocardial ischemic lesion, or a myocardial infarction.
Claim 15
Dependent Claim
26 words
Composition of claim 1, 2 or 3, wherein the essentially ganglioside, lipid or ganglioside-lipid-omental material leads to improvement of vascularization and perfusion in a transplanted heart.
Claim 16
Dependent Claim
47 words
Composition of claims 1, 2 or 3, wherein the essentially ganglioside, lipid, or ganglioside-lipid-omental material leads to improvement of a vascular bed supplied by an aortic and peripheral vascular and cardiac coronary graft and in a vessel reopened by techniques such as but not limited to angioplasty.
Claim 17
Dependent Claim
37 words
Composition of claims 1, 2 or 3, wherein the essentially ganglioside, lipid or ganglioside-lipid-omental material leads to increased perfusion, vascularization and collateralization, organization and collagenization in angina, a myocardial ischemic lesion, and a myocardial infarct in humans.
Claim 18
Dependent Claim
71 words
Method for the treatment of angina, a myocardial ischemic lesion or a myocardial infarction condition in a patient having angina, a myocardial infarct or a myocardial ischemic lesion which comprises using physiologically active amounts of a mixture of isolated lipid and ganglioside material derived from the omentum by extraction with at least one organic solvent in a physiologically active amount sufficient to observe enhanced perfusion, vascularization or collateralization in said condition.
Claim 19
Dependent Claim
71 words
Method for the treatment of angina, a myocardial ischemic lesion or a myocardial infarction condition in a patient having angina, a myocardial infarct or a myocardial ischemic lesion which comprises using physiologically active amounts of a mixture of isolated lipid and ganglioside material derived from the omentum by extraction with at least one organic solvent in a physiologically active amount sufficient to observe enhanced perfusion, vascularization or collateralization in said condition.
Claim 20
Dependent Claim
13 words
Method of claim 15 wherein the omentum derived material consists essentially of lipid.
Claim 21
Dependent Claim
13 words
Method of claim 15 wherein the omentum derived material consists essentially of ganglioside.
Claim 22
Dependent Claim
13 words
Method of claim 15 wherein the physiologically active extract is a chloroform-methanol extract.
Claim 23
Dependent Claim
13 words
Method of claim 15 wherein the physiologically active extract is a hexane-ethanol extract.
Claim 24
Dependent Claim
18 words
Method of claim 19 wherein the physiologically active extract is a hexane-ethanol extract derived from the chloroform-methanol extract.
Claim 25
Dependent Claim
43 words
Method for the treatment of angina, a myocardial ischemic lesion or a myocardial infarction condition in a patient having angina, a myocardial infarct or a myocardial ischemic lesion which comprises using physiologically active amounts of a mixture of a purified lipid and ganglioside.
Claim 26
Dependent Claim
43 words
Method for the treatment of angina, a myocardial ischemic lesion or a myocardial infarction condition in a patient having angina, a myocardial infarct or a myocardial ischemic lesion which comprises using physiologically active amounts of a mixture of a purified lipid and ganglioside.
Claim 27
Dependent Claim
13 words
Method of claim 21 wherein the physiologically active material consists essentially of lipid.
Claim 28
Dependent Claim
13 words
Method of claim 21 wherein the physiologically active material consists essentially of ganglioside.
Claim 29
Dependent Claim
23 words
Method of claims 15, 16, 17, 21, 22 or 23 wherein the essentially ganglioside, lipid or lipid-ganglioside material enhances perfusion in said conditions.
Claim 30
Dependent Claim
23 words
Method of claims 15, 16, 17, 21, 22 or 23 wherein the essentially ganglioside, lipid or lipid-ganglioside material improves collagenation in said conditions.
Claim 31
Dependent Claim
26 words
Method of claims 15, 16, 17, 21, 22 or 23 wherein the essentially ganglioside, lipid or lipid-ganglioside material leads to improved scar formation in said conditions.
Claim 32
Dependent Claim
30 words
Method of claims 16, 17, 17, 21, 22 or 24 wherein the essentially ganglioside, lipid or lipid-ganglioside material leads to improvement of vascularization, collateralization and perfusion in a transplanted heart.
Claim 33
Dependent Claim
51 words
Method of claims 15, 16, 17, 21, 22 or 23 wherein the essentially ganglioside, lipid or lipid-ganglioside material leads to improvement of a vascular bed supplied by an aortic, a peripheral vascular graft, a cardiac coronary graft and in a vessel reopened by techniques such as but not limited to angioplasty.
References Cited (Backward Citations)
US2788308A
Cited
US2845381A
Cited
US3017325A
Cited
US3047470A
Cited
US3318901A
Cited
US3271394A
Cited
US3341410A
Cited
US3395223A
Cited
US3321484A
Cited
US3518243A
Cited
US3522229A
Cited
US3672954A
Cited
US3622668A
Cited
US3809760A
Cited
US3767683A
Cited
US3920848A
Cited
US4029773A
Cited
US3949073A
Cited
US4233360A
Cited
US4211782A
Cited
US4282250A
Cited
US4333940A
Cited
US4376781A
Cited
US4455298A
Cited
US4447418A
Cited
US4420339A
Cited
US4456596A
Cited
US4427650A
Cited
US4442655A
Cited
US4476119A
Cited
USPTO Annuity & Maintenance Windows
| Annuity Stage | Window Opens | Payment Deadline | Surcharge Period Until | Estimated Fee | Status |
|---|---|---|---|---|---|
| 3.5 Years (Year 4) | 1991-10-18 | 1992-04-18 | 1992-10-18 | $2000.00 | Window Closed / Lapsed |
| 7.5 Years (Year 8) | 1995-10-18 | 1996-04-18 | 1996-10-18 | $3760.00 | Window Closed / Lapsed |
| 11.5 Years (Year 12) | 1999-10-18 | 2000-04-18 | 2000-10-18 | $7700.00 | Window Closed / Lapsed |